High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciab162
PubMed Identifier: 33693537
Publication URI: http://europepmc.org/abstract/MED/33693537
Type: Journal Article/Review
Parent Publication: Clinical Infectious Diseases
Issue: 5
ISSN: 1058-4838